Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Stock Information | RedChip

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Listen to this Section


$0.60
+0.0185 ( +3.16% ) 1.1M

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Market Data


Open


$0.60

Previous close


$0.59

Volume


1.1M

Market cap


$109.00M

Day range


$0.59 - $0.62

52 week range


$0.48 - $1.07

Insider Ownership Transactions

Total Amount Purchased: -2,669,498.00 | $ -1,614,512.39

Date Type Amount Purchased Purchaser
2024-04-05 Sale -129450.00 HOLUBIAK MYRON Z
2024-04-05 Sale -1165048.00 Mazur Leonard L
2024-03-18 Sale -75000.00 Smith Robert Joseph
2023-10-12 Sale -75000.00 Webb Carol
2023-10-12 Sale -300000.00 Czuczman Myron
2023-10-12 Sale -400000.00 HOLUBIAK MYRON Z
2023-10-12 Sale -75000.00 Holuka Eugene Myron
2023-10-12 Sale -75000.00 Dutia Suren G
2023-10-12 Sale -300000.00 Bartushak Jaime
2023-10-12 Sale -75000.00 MCGRATH DENNIS M

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 15 Aug 12, 2024
10-q Quarterly Reports 58 Aug 12, 2024
8-k 8K-related 16 Aug 08, 2024
8-k 8K-related 15 May 21, 2024
10-q Quarterly Reports 55 May 14, 2024
8-k 8K-related 15 May 14, 2024
8-k 8K-related 18 Apr 30, 2024
4 Insider transactions 1 Apr 05, 2024
8-k 8K-related 13 Apr 05, 2024
4 Insider transactions 1 Apr 05, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.